Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PP2A-Cα) is the major catalytic component of the heterotrimeric protein phosphatase 2A (PP2A) enzyme complex, which mediates dephosphorylation of serine and threonine residues on diverse substrate proteins[4][2]. The PP2A complex is involved in numerous critical cellular processes including regulation of signal transduction, cell cycle, apoptosis, and cellular metabolism, frequently acting as a tumor suppressor[2][7]. Dysfunction, mutation, or altered expression of PP2A is implicated in cancer, neurodegeneration, and other diseases[1][2]. Multiple drugs inhibit or modulate PP2A activity, and the enzyme is a focus of interest for therapeutic targeting in cancer and possibly other diseases[7].
Inhibition of PP2A activity (by drugs such as cantharidin and okadaic acid); Modulation of phosphorylation states of key signaling proteins (downstream effects)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PP2A-Cα).